⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2019Annals of OncologyOpen Access

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

ClinicalTrials.gov identifier NCT00585195.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shaw et al. (2019) studied this question.

synapsesocial.com/papers/69d76859aa68b335b4f3154c https://doi.org/10.1093/annonc/mdz131

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyondEarly-Phase Clinical Trial · 2011 · 183 citations
2Identifying and Targeting <i>ROS1</i> Gene Fusions in Non–Small Cell Lung CancerOriginal Research · 2012 · 475 citations
3Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung CancerOriginal Research · 2014 · 2,015 citations
4<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung CancersRetrospective Study · 2012 · 1,569 citations
5Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer2018 · 419 citations